The Peptide Gold Rush: Why the Hype is Running Ahead of the Evidence
GLP-1s changed the conversation. Suddenly the word peptide was everywhere: in chats about weight loss, on social media, in the supplement aisle, and increasingly, in vials that people are injecting at home.
It is not surprising that the interest has spilled beyond Ozempic and Wegovy. If one peptide can do that, what about all the others? Cue a wave of "peptide stacks" being promoted online for everything from skin quality and hair growth to recovery, sleep, and so-called longevity.
But here is what doesn't get said quite enough: the evidence base for most of these peptides is nothing like the evidence base for the GLP-1s. And a sizeable chunk of what is being injected is being purchased, shipped, and self-administered completely outside any meaningful medical or regulatory framework.
We need to talk about it.
What are peptides, anyway?
A peptide is, simply, a short chain of amino acids. It is smaller than a protein, but more than a single amino acid on its own. Peptides act as signalling molecules. They tell cells to do things the body already knows how to do: building, repairing, regulating, releasing.
Some peptides are extraordinary medicines. Insulin is a peptide. So is glucagon. So are the GLP-1 receptor agonists transforming metabolic medicine. Peptide-based therapies are used thoughtfully and routinely across mainstream practice.
Other peptides sit in a very different place: early research, animal studies, theoretical mechanisms, enthusiastic online communities - and very little robust human data. The marketing rarely makes that distinction. And you can be sure that your TikTok feed certainly doesn't.
The current state of play
In the US, the FDA looks set to revisit its 2023 restrictions on a group of fourteen peptides, with a review meeting on a subset of them scheduled for this year. Those fourteen peptides were placed in what is called Category 2 meaning compounding pharmacies were told they could not legally produce them, because the regulator had identified safety concerns or a lack of adequate human data.
This was not a paperwork issue. It was a "we don't have good enough evidence that this is safe" issue.
A possible reversal is not the same thing as a green light. Even if these peptides are taken back out of Category 2, that doesn't make them FDA-approved drugs. It would simply mean compounding pharmacies could produce them again under prescription. The evidence base for safety and efficacy would not have changed. The labelling would not say "this works." It would just mean the bottleneck on supply got smaller.
That matters, because the demand is already there.
So which peptides are we actually talking about?
Several names on the restricted list are being marketed heavily in the aesthetic and wellness space:
GHK-Cu — a copper-binding tripeptide, promoted for skin healing, anti-ageing, and hair growth.
Epitalon — a synthetic peptide originally researched in Russia in the 1980s, marketed for "longevity" and pineal function.
KPV — a tripeptide explored in early research for inflammatory bowel disease and inflammatory skin conditions.
Melanotan II — a synthetic analogue of α-MSH that stimulates melanin production. Sold online for tanning.
BPC-157 — "Body Protection Compound." Derived from a sequence found in gastric juice. Marketed extensively for recovery, healing, and gut health.
The claims around each of these can sound compelling — until you look at where the evidence actually comes from.
The evidence problem
Take GHK-Cu. There is genuinely interesting research on copper peptides in topical skincare, and you'll find them in formulations from reputable cosmeceutical brands. The systemic, injectable use of GHK-Cu is a different proposition entirely, and it does not have the same evidence base. Conflating the two is a common marketing sleight of hand.
BPC-157 has generated a lot of interesting animal data, particularly in rodent models of soft tissue healing. Robust human trials are vanishingly thin on the ground. We do not have good data on long-term safety, optimal dosing, or who shouldn't use it.
Epitalon has a body of literature, much of which comes from a single research programme, and most of which is small, unblinded, and decades old.
KPV has early research as a potential anti-inflammatory, but mostly preclinical, mostly in IBD. That is a long way from "rub this on your eczema" or "inject yourself for clearer skin."
And then there is Melanotan II. This is the one I want to flag most strongly. There are documented case reports associating Melanotan II use with new and changing melanocytic naevi, and in some cases melanoma. The MHRA and the British Association of Dermatologists have been warning about this for over a decade, with documented case reports going back to 2009. The mechanism is biologically plausible - after all, you are systemically driving melanocyte activity - and the risk is real, not theoretical. As a doctor working in skin every single day, I would not want anyone reading this to be using it.
The "research use only" loophole
You can buy almost all of the peptides on the restricted list online, today. You tick a box saying you are using them for research and not for human or animal consumption, and the vial arrives at your door. A vial of BPC-157 sits at around $120.
This is a loophole, not a regulatory blessing. The "research use only" label exists so that genuine laboratory research can purchase reagents. It was never designed as a workaround for selling unapproved injectables to consumers. Vendors use it to dodge medicines law. Buyers use it to access products they couldn't otherwise legally obtain. Nobody is genuinely fooled - but as long as the paperwork says one thing, the legal risk to the seller is limited.
What is in those vials is a separate question, and frankly, the one that concerns me most.
What is actually in the vial?
Unregulated peptide products do not have to demonstrate:
Sterility. Injecting a non-sterile product directly into your tissues is a serious infection risk.
Purity. Is the listed peptide actually present in the listed dose? Are there contaminating peptides, synthesis byproducts, or fillers?
Endotoxin testing. Bacterial endotoxin contamination is a real and dangerous possibility in poorly manufactured biologics.
Quality control documentation. Where was it made? Under what conditions? By whom?
Many of these products are manufactured overseas, in facilities that have never been inspected by any regulator. You are, essentially, trusting an anonymous online vendor with something going under your skin.
Even if the peptide inside did everything it claims, you wouldn't be getting just the peptide.
But the UK - surely we're better protected?
Partially.
UK compounding is far more tightly controlled than in the US. The MHRA regulates medicines, the GPhC regulates pharmacies, and the "specials" framework - which lets pharmacists prepare unlicensed medicines - is narrow and clinically driven. You will not easily find a UK pharmacy openly producing Melanotan II for aesthetic use.
That doesn't mean the problem skips us.
Online vendors ship globally. UK-based clinics offering "peptide therapy" can absolutely be sourcing from less reputable suppliers, and the language gets clever - "research peptides,""performance support,""longevity protocols." Patients can, and do, order these themselves and inject at home. The UK regulatory framework only protects you if the product passed through it.
It very often hasn't.
How to think about this if you're being offered peptides
If a clinic, online programme, or wellness coach is offering you peptides, a few useful questions:
Where is the peptide sourced from? A regulated pharmacy with proper documentation, or somewhere they would rather not say?
What evidence exists in humans? At what doses, for what duration, with what monitoring?
Who is medically responsible? Will there be bloods, follow-up, and someone equipped to manage a complication if one occurs?
Is there a licensed alternative? Sometimes there is, with vastly better evidence behind it.
If the answers are evasive - heavy on transformation, light on data - that is the information you needed.
My bottom line
I am not anti-peptide. Peptides are a genuinely exciting area of medicine, and some of them will turn out to be important future therapies. Evidence-based peptide medicine has a real future, and I fully expect aesthetics to benefit as the science matures.
But that future depends on doing the work: proper trials, proper manufacturing, proper prescribing, proper monitoring. Not vials shipped from an unknown warehouse with a sticker that says "not for human use."
A possible US regulatory change won't, by itself, make any of these compounds safe. Compounded is not the same as approved. Available is not the same as evidenced. Popular is definitely not the same as wise.
If you're curious about peptides - for skin, hair, recovery, or anything else - bring that curiosity to a clinician who can assess whether there is a genuine intervention worth considering. Or whether what you are being sold is, medically speaking, very expensive magic beans.
References
Regulatory framework and the proposed reversal
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Available at: fda.gov
Regulatory Affairs Professionals Society (RAPS). FDA considers adding a dozen peptides to its bulk drug compounding list. April 2026. Available at: raps.org
Stone W. The government may soon lift restrictions on some peptide treatments. NPR Health, 2026. Available at: npr.org
ProPublica. Peptide safety, FDA, and compounding pharmacies. Available at: propublica.org
Peptide-specific evidence
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. doi: 10.1177/15563316251355551
Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi: 10.3390/ijms19071987
Melanotan II — case literature
Langan EA, Ramlogan D, Jamieson LA, Rhodes LE. Change in moles linked to use of unlicensed "sun tan jab". BMJ. 2009;338:b277. doi: 10.1136/bmj.b277
Cousen P, Colver G, Helbling I. Eruptive melanocytic naevi following melanotan injection. British Journal of Dermatology. 2009;161(3):707-708. doi: 10.1111/j.1365-2133.2009.09362.x
Paurobally D, Jason F, Dezfoulian B, Nikkels AF. Melanotan-associated melanoma. British Journal of Dermatology. 2011;164(6):1403-1405. doi: 10.1111/j.1365-2133.2011.10273.x
Ong S, Bowling J. Melanotan-associated melanoma in situ. Australasian Journal of Dermatology. 2012;53(4):301-302. doi: 10.1111/j.1440-0960.2012.00915.x
Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ. 2009;338:b566. doi: 10.1136/bmj.b566
UK regulatory and professional positions
Medicines and Healthcare products Regulatory Agency (MHRA). "Tan jab" is an unlicensed medicine and may not be safe — warns medicines regulator. Press release, 2008. National Archives version: webarchive.nationalarchives.gov.uk
British Association of Dermatologists. Public statements on Melanotan and tanning injections. Further information available at: bad.org.uk
Peptide injections are everywhere — from BPC-157 and GHK-Cu to Melanotan II and epitalon — promoted online for skin, hair, recovery, and "longevity." With the FDA reportedly poised to reverse 2023 restrictions on fourteen peptides, demand is set to grow even further. But the gray-market peptide trade operates almost entirely outside medical regulation, and the evidence base for most of these compounds is far weaker than the marketing suggests.
Let’s break down what peptides actually are, where the real risks lie, and how to evaluate any peptide therapy you are offered.